The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ISAL 2019 | Checkpoint inhibitor combination approaches for AML/MDS: an update
Naval Daver, MD, of the University of Texas MD Anderson Cancer Center, Houston, TX, gives us an update on promising checkpoint inhibitor combination approaches for acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). This interview was recorded at the International Symposium on Acute Leukemias (ISAL) 2019, held in Munich, Germany.
